SCARB2 variants and glucocerebrosidase activity in Parkinson’s disease

[1]  W. Chung,et al.  Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. , 2015, Brain : a journal of neurology.

[2]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[3]  W. M. van der Flier,et al.  Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies , 2014, Human molecular genetics.

[4]  V. Meiner,et al.  A novel SCARB2 mutation in progressive myoclonus epilepsy indicated by reduced β-glucocerebrosidase activity , 2014, Journal of the Neurological Sciences.

[5]  W. Chung,et al.  Knowledge of and Interest in Genetic Results Among Parkinson Disease Patients and Caregivers , 2014, Journal of Genetic Counseling.

[6]  Z. Katsarou,et al.  Association study of rs6812193 polymorphism with Parkinson's disease in a Greek population , 2013, Neuroscience Letters.

[7]  C. Gieger,et al.  The role of SCARB2 as susceptibility factor in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[8]  E. Sidransky,et al.  Is Parkinson disease associated with lysosomal integral membrane protein type-2?: challenges in interpreting association data. , 2013, Molecular genetics and metabolism.

[9]  Ying Wang,et al.  Association study of SCARB2 rs6812193 polymorphism with Parkinson's disease in Han Chinese , 2012, Neuroscience Letters.

[10]  D. Vassilatis,et al.  Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[11]  W. Hwu,et al.  The use of dried blood spot samples in the diagnosis of lysosomal storage disorders--current status and perspectives. , 2011, Molecular genetics and metabolism.

[12]  Nicholas Eriksson,et al.  Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease , 2011, PLoS genetics.

[13]  J. Stockman.  Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .

[14]  G. Rubboli,et al.  Biochemical and molecular findings in a patient with myoclonic epilepsy due to a mistarget of the beta-glucosidase enzyme. , 2009, Molecular genetics and metabolism.

[15]  A. Singleton,et al.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.

[16]  Kate Zhang,et al.  An improved high-throughput dried blood spot screening method for Gaucher disease. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[17]  W. Chuang,et al.  Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. , 2008, Clinical chemistry.

[18]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[19]  E D Louis,et al.  Accuracy of family history data on Parkinson’s disease , 2003, Neurology.

[20]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.